{"id":66956,"date":"2026-06-01T14:54:31","date_gmt":"2026-06-01T06:54:31","guid":{"rendered":"https:\/\/flcube.com\/?p=66956"},"modified":"2026-06-01T14:54:32","modified_gmt":"2026-06-01T06:54:32","slug":"shandong-boan-submits-dual-denosumab-biosimilar-blas-to-fda-for-osteoporosis-and-oncology-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66956","title":{"rendered":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shandong Boan Biotechnology Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>)<\/strong> announced the submission of <strong>Biologics License Applications (BLAs)<\/strong> to the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for two denosumab biosimilars: <strong>BA6101<\/strong> (biosimilar to Amgen&#8217;s <strong>Prolia<\/strong>) and <strong>BA1102<\/strong> (biosimilar to Amgen&#8217;s <strong>Xgeva<\/strong>). The applications seek approval for the <strong>full range of originator indications<\/strong>, positioning Boan to capture significant share in both the <strong>osteoporosis<\/strong> and <strong>oncology bone health markets<\/strong> with comprehensive therapeutic coverage across Amgen&#8217;s $6+ billion annual denosumab franchise.<\/p>\n\n\n\n<h2 id=\"h-regulatory-filing-details\" class=\"wp-block-heading\">Regulatory Filing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Filing Type<\/strong><\/td><td>Biologics License Applications (BLAs)<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>BA6101 (Prolia biosimilar) and BA1102 (Xgeva biosimilar)<\/td><\/tr><tr><td><strong>Reference Products<\/strong><\/td><td>Amgen&#8217;s Prolia (denosumab) and Xgeva (denosumab)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><tr><td><strong>Indication Coverage<\/strong><\/td><td>Full label extrapolation covering all originator indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-portfolio-amp-indications\" class=\"wp-block-heading\">Product Portfolio &amp; Indications<\/h2>\n\n\n\n<h3 id=\"h-ba6101-prolia-biosimilar\" class=\"wp-block-heading\">BA6101 (Prolia Biosimilar)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Indications<\/strong>: Treatment and prevention of <strong>osteoporosis-related conditions<\/strong><\/li>\n\n\n\n<li><strong>Target Populations<\/strong>: Postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis<\/li>\n\n\n\n<li><strong>Therapeutic Goal<\/strong>: Reduce fracture risk through RANK ligand inhibition<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-ba1102-xgeva-biosimilar\" class=\"wp-block-heading\">BA1102 (Xgeva Biosimilar)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Indications<\/strong>:<\/li>\n\n\n\n<li><strong>Bone metastases<\/strong> from solid tumors<\/li>\n\n\n\n<li><strong>Multiple myeloma<\/strong> (prevention of skeletal-related events)<\/li>\n\n\n\n<li><strong>Giant cell tumor of bone<\/strong> (unresectable or surgically challenging cases)<\/li>\n\n\n\n<li><strong>Hypercalcemia<\/strong> of malignancy refractory to bisphosphonate therapy<\/li>\n\n\n\n<li><strong>Therapeutic Goal<\/strong>: Prevent skeletal-related events and manage bone complications in cancer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Boan&#8217;s dual BLA submission addresses Amgen&#8217;s <strong>integrated denosumab franchise<\/strong>, which generated approximately <strong>$6.2 billion in global sales in 2025<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Segmentation<\/strong>: Simultaneous entry into both <strong>chronic care (Prolia)<\/strong> and <strong>oncology (Xgeva)<\/strong> markets<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Expected <strong>30\u201340% cost reduction<\/strong> compared to originator products<\/li>\n\n\n\n<li><strong>Healthcare Impact<\/strong>: Potential to significantly reduce U.S. healthcare system costs for bone health management<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Among the first wave of denosumab biosimilars seeking FDA approval<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This dual BLA submission represents a major milestone in our mission to provide high-quality, affordable biologics to patients worldwide,&#8221; said Dr. Wang Li, Chief Executive Officer of Shandong Boan Biotechnology. &#8220;By addressing both osteoporosis and oncology indications with comprehensive biosimilar coverage, we aim to improve access to essential bone health therapies while generating substantial savings for the U.S. healthcare system.&#8221;<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-commercial-outlook\" class=\"wp-block-heading\">Competitive Landscape &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The U.S. denosumab biosimilar market is poised for significant disruption:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent Expiry<\/strong>: Amgen&#8217;s key patents expired in 2025, opening the market to biosimilar competition<\/li>\n\n\n\n<li><strong>Addressable Market<\/strong>: Combined U.S. market opportunity estimated at <strong>$3\u20134 billion annually<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: FDA&#8217;s established biosimilar approval framework provides clear development requirements<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Immediate eligibility for inclusion in pharmacy benefit manager (PBM) formularies and hospital group purchasing organization (GPO) contracts<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts expect the first denosumab biosimilars to launch in <strong>Q2\u2013Q3 2027<\/strong>, with Boan well-positioned to capture significant market share given its comprehensive indication coverage and established manufacturing capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory submissions, market opportunities, and commercial expectations for BA6101 and BA1102. Actual results may differ due to FDA review outcomes, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026052902129_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052902129_c.\"><\/object><a id=\"wp-block-file--media-0c2c48a8-4db0-419f-a42b-b2f04939040a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026052902129_c.pdf\">2026052902129_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026052902129_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0c2c48a8-4db0-419f-a42b-b2f04939040a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,220,1024,38],"class_list":["post-66956","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biosimilars","tag-boan-biotechnology","tag-hkg-6955","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen&#039;s Prolia) and BA1102 (biosimilar to Amgen&#039;s Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen&#039;s $6+ billion annual denosumab franchise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66956\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen&#039;s Prolia) and BA1102 (biosimilar to Amgen&#039;s Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen&#039;s $6+ billion annual denosumab franchise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66956\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:54:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T06:54:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications\",\"datePublished\":\"2026-06-01T06:54:31+00:00\",\"dateModified\":\"2026-06-01T06:54:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"HKG: 6955\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66956#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66956\",\"name\":\"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T06:54:31+00:00\",\"dateModified\":\"2026-06-01T06:54:32+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen's Prolia) and BA1102 (biosimilar to Amgen's Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen's $6+ billion annual denosumab franchise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66956\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66956#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen's Prolia) and BA1102 (biosimilar to Amgen's Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen's $6+ billion annual denosumab franchise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66956","og_locale":"en_US","og_type":"article","og_title":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen's Prolia) and BA1102 (biosimilar to Amgen's Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen's $6+ billion annual denosumab franchise.","og_url":"https:\/\/flcube.com\/?p=66956","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:54:31+00:00","article_modified_time":"2026-06-01T06:54:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66956#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66956"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications","datePublished":"2026-06-01T06:54:31+00:00","dateModified":"2026-06-01T06:54:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66956"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Boan Biotechnology","HKG: 6955","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66956#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66956","url":"https:\/\/flcube.com\/?p=66956","name":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T06:54:31+00:00","dateModified":"2026-06-01T06:54:32+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen's Prolia) and BA1102 (biosimilar to Amgen's Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen's $6+ billion annual denosumab franchise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66956#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66956"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66956#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66956"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66956\/revisions"}],"predecessor-version":[{"id":66958,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66956\/revisions\/66958"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}